Genetic Technologies Ltd is an Australia-based molecular diagnostics company which offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and the United States.
| Website: | www.gtglabs.com |
| Main Phone: | +61 384127000 |
| Address: | 60-66 Hanover Street |
| Address 2: | P.O. Box 115 |
| State: | VIC |
| City / Town: | Fitzroy |
| Country: | AUS |
| Postal Code: | 3065 |
| Exchange: | NSC |
| CEO: | Paul A. Kasian |
| Employees: | 16 |
| NAICS: | Biological Produ |
| Last Price 0.76 | Change $ -0.1 | Change % -11.63 | Tick N/A |
| Bid 0.62 | Bid Size 300.00 | Ask 0.75 | Ask Size 1,600.00 |
| Open 0.82 | High 0.86 | Low 0.69 | Prev Close 0.86 |
| Last Trade | Volume 175,561 | 52 Wk Hi 2.05 | 52 Wk Low 0.69 |
| Market Cap 12.3 mi | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares 16,235,218.00 | EPS (TTM) -0.24 | PE Ratio N/A | Exchange NCM |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 2.5 | 2.5 | 2.5 | 2.5 |
| Low Target Price Estimate | 2.5 | 2.5 | 2.5 | 2.5 |
| Mean Target Price Estimate | 2.5 | 2.5 | 2.5 | 2.5 |
| Standard Deviation | 0 | 0 | 0 | 0 |
| Date of Most Recent Estimate | 09/02/14 | 09/02/14 | 09/02/14 | 09/02/14 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| 6-K | Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act | 5 | 2018-06-07 |
| 6-K | Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act | 5 | 2018-05-01 |
| 6-K | Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act | 12 | 2018-04-30 |
| 6-K | Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act | 5 | 2018-03-16 |
| 6-K | Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act | 5 | 2018-03-08 |
| 6-K | Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act | 24 | 2018-02-27 |
| 6-K | Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act | 10 | 2018-02-15 |
| SC 13G | Statement of beneficial ownership of common stock by certain persons | 1 | 2018-02-14 |
| 6-K | Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act | 5 | 2018-02-13 |
| SC 13G/A | Amendment to the SC 13G filing | 7 | 2018-02-09 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 |
| Moderate Buy | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 1 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 0 | 0 | 0 | 3 |
© 2018 Equities
* All dates and time are being displayed in Eastern Standard Time (EST).
